← Eichor
Condition: Cholangiocarcinoma Metastatic Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cholangiocarcinoma Metastatic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Phase 2 · 44 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT05678270Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Phase 2 · 2 location(s) · Case Comprehensive Cancer Center · NCT07146646Intravital Microscopy in Human Solid Tumors
NA · 1 location(s) · Mayo Clinic · NCT03823144Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
Phase 2 · 1 location(s) · Michael J Cavnar, MD · NCT07201519Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepati
Phase 2 · 7 location(s) · University Hospital, Montpellier · NCT03364530Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced
Phase 2 · 1 location(s) · West China Hospital · NCT06859684Liver Transplantation in Intrahepatic Cholangiocarcinoma
Phase N/A · 2 location(s) · Rutgers, The State University of New Jersey · NCT06140134Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06126406PULSAR Combined With Immunotherapy and Chemotherapy
Phase 1/Phase 2 · 1 location(s) · Wang Xin · NCT07291947Scout Dose of Resin Microspheres
NA · 1 location(s) · Seoul National University Hospital · NCT07476651Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06010862SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Liver Embolization Approaches for Tumor Management
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT05714124TCF-001 TRACK (Target Rare Cancer Knowledge) Study
NA · 1 location(s) · TargetCancer Foundation · NCT04504604A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Phase 1 · 2 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06043466Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Meta
Phase 1/Phase 2 · 38 location(s) · Institut de Recherches Internationales Servier · NCT06501625Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Phase 1 · 4 location(s) · Tyra Biosciences, Inc · NCT06160752An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Phase 3 · 84 location(s) · Servier Affaires Médicales · NCT05876754AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
Phase 1 · 2 location(s) · University of Southern California · NCT05791448Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Phase 2 · 41 location(s) · UNICANCER · NCT06529718A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cis
Phase 1/Phase 2 · 1 location(s) · Shanghai 6th People's Hospital · NCT07632235PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05430698CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035Streamlining Radioembolization for CCC and Metastatic Liver Cancer
Phase N/A · 4 location(s) · Seoul National University Hospital · NCT07043387High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05053555PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Color
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05286814Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemi
Phase N/A · 13 location(s) · iOMEDICO AG · NCT06607302The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
NA · 1 location(s) · New Phase Ltd. · NCT07224464Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07641036
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.